Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Optimierung der Ernährung und Medikation für akut aufgenommene ältere medizinische Patienten (OptiNAM)

10. November 2026 aktualisiert von: Ove Andersen, Hvidovre University Hospital

Malnutrition and inappropriate medication prescribing are highly prevalent among acutely admitted older medical patients leading to re-admissions, frailty, poor physical, performance compromised quality of life and mortality. Thus, the aim of this study is to optimise the nutrition and medication in older medical patients admitted to an acute care department at admission and up to 16 weeks after discharge. Participants in the intervention group receives a medication review and participants with malnutrition or risk of malnutrition additionally receive a transitional multimodal intervention. The control group receives standard care.

Studienübersicht

Detaillierte Beschreibung

The OptiNAM study is designed as a single-blinded randomised controlled trial starting upon admission and continues till 16 weeks after discharge. The trial has five sub-studies with three independent primary endpoints, all with individual sample size calculations.

The study consists of an intervention group and a control group. The control group receives standard care.

Patients that meet all inclusion criteria and none of the exclusion criteria are invited to participate. After signing a written informed consent, the participants are block randomised to either the intervention or control group.

The intervention group receives a personalised rehabilitation program, which is described below. Outcome measures are performed at baseline, week 8 and week 16 after after discharge, cf. section regarding outcome measures.

Sub study 1, Malnutrition:

As malnutrition among older patients has multifactorial etiology sub-study 1 investigates the effects of a multimodal transitional intervention on quality of life in acutely admitted older patients with malnutrition or risk of malnutrition (according to the Mini Nutritional Assessment - Short Form) from baseline (admission day) and 16 weeks after discharge compared to standard care. The intervention includes a medication review (cf. sub-study 2), a dietetic intervention and if clinical relevant physiotherapeutic-, occupational-, geriatric- and/or odontological intervention. It is secondary hypothesised that a multimodal intervention compared to standard care may improve the quality of life, nutritional status, energy- and protein intake, symptoms which compromise nutritional intake, physical performance, cognitive function, frailty, re-admissions, inflammation and biomarkers. A cost-benefit analysis will be conducted.

Dietetic intervention: The study subjects receives a personal diet plan during admission. The diet plan is reviewed at discharge by a dietician. To ensure optimal energy- and protein intake after discharge, a community-based dietician visit the participants for one hour in week 1, 2, 4 and 8.

Physiotherapeutic intervention: Participants with low ability to perform groceries shopping, cooking and/or eating are offered a community-based strength, balance and endurance training after discharge if they also have low muscle strength in the lower extremities. The training sessions are based on algorithms, have a duration of one hour, and are offered twice a week for 16 weeks after discharge.

Occupational intervention, Dysphagia: If relevant (EAT-10 score >=3), a hospital-based occupational therapist review and treat the dysphagia based on the Facial Oral Tract Therapy (FOTT) principle during admission. During the first week after discharge a community-based occupational therapist continues with the treatment. A maximum of two weekly visits of one hour throughout the interventions period is offered.

Occupational Intervention, low Ability to perform Activities of Daily Living (ADL): If the participant has low ability to perform grocery shopping, cooking and eating (evaluated by Functional Recovery Score <=2) then a community-based occupational therapist visit the participant during the first two weeks after discharge to evaluate the quality of activities of daily living. If relevant, and if there is a rehabilitation potential, seven visits of one hour is offered during the 16 weeks after discharge.

Geriatric intervention: If relevant (a Mini Geriatric Depression Score >=2), a geriatric physician conducts a clinical assessment of depression during admission and initiate treatment if necessary.

Odontological intervention: If relevant (participant reported pain in mouth, difficulties chewing or xerostomia), a dentist evaluate the dental status and oral health during admission, and if necessary encourage the participant to consult a dentist after discharge. If a participant shows insufficient oral hygiene a dental hygienist visits the participant after discharge twice during after discharge.

Sub-study 2, Medication optimisation:

Medication prescription for older patients is challenging and may be attributed to marked inter-individual variations in general health, comorbidities, organ function, pharmacokinetic and pharmacodynamic properties, biological age and physical performance. Thus, the "one size fits all" approach is probably inappropriate in older patients. The aim of sub-study 2 is to investigate the investigate the effect of an inter-professional conducted medication review during admission in an acute care department regardless of the nutritional status in the study participant, thus all subjects in the intervention group receive a medication review. It is hypothesized that inter-professional conducted medication reviews reduce the Medication Appropriateness Index score (MAI score) in the intervention group eight weeks after discharge compared to the control group. It is secondary hypothesized that inter-professional conducted medication reviews improve: lack of medication prescribing for a condition/disease, inappropriate polypharmacy and suboptimal medication prescribing of high risk medications.

Sub-study 3, Accuracy of renal function estimates and the consequence for prescribing recommendations guidelines:

Accuracy in renal function estimates is essential for optimization of medication prescribing since 40 % of all medication or their active metabolites is renally excreted. Lack of medication prescribing and dose adjustment according to the renal function is common in older patients with renal impairment and can result in overdosing, adverse drug reactions, hospital admissions, reduced quality of life and mortality. The gold standard for measuring glomerular filtration rate (GFR) is an exogenous filtration marker. However, this method is costly, time consuming and thus impractical in a clinical setting. Therefore, GFR is often estimated on serum concentrations of an endogen biomarker. Sub-study 3 aim to investigate which biomarker(s) and equation most accurately estimate the GFR in older medical patients who have been acutely admitted.

Sub-study 4, Pharmacogenetic test on cytochrome 450 variations and its potential for optimization of medication prescribing:

Cytochrome 450 enzymes are responsible for metabolism of up to 80% of all medications. The enzyme complex is mainly found in liver but are also present in intestinal mucosa, skin, lungs, brain and kidneys. There are major genetic inter-individual differences in the activity of the CYP 450 complex, resulting in lack of therapeutic effects, lack of effect or adverse drug reactions. Insight into these genetic inter-individual differences via pharmacogenetic tests possess a potential in optimization of medication prescribing with regard to therapeutic effects, compliance and risk of side effects. Thus, sub-study 4 wish to descriptively investigate the potential of pharmacogenetic test on cytochrome 450 variations.

Sub-study 5, Assessment of Frailty:

Frailty is a common clinical syndrome in older adults and defined as state of increased vulnerability resulting from decline in reserve capacity and function across multiple physiologic systems. Frailty affects the person's ability to cope with everyday life and leads to high risk for falls, disability, hospitalization and mortality. The frailty assessment is based on two different frailty scoring systems, Frieds "Frailty Phenotype" and Morley's "Frail Scale", examined at admission and 8 and 16 weeks after discharge. The purpose of the assessment is to evaluate which frailty measure is the best applicable in describing the patients and changes in their functional level. As there is no gold standard we use FI-Outref as an independent measure of frailty. FI-OutRef is a Frailty Index, based on standard admission laboratory test results Outside of the Reference interval.

Studientyp

Interventionell

Einschreibung (Tatsächlich)

193

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • Capital Region
      • Hvidovre, Capital Region, Dänemark, 2650
        • Amager & Hvidovre Hospital

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

65 Jahre und älter (Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • ≥65 years
  • Acutely admitted medical patients
  • Understand and speak Danish
  • Caucasian
  • Resident in Municipality: Brøndby, Hvidovre or Copenhagen

Exclusion Criteria:

  • Unable to cooperate cognitively
  • Terminal/suicidal patients
  • Patients in isolation

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Single

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Optimisation of nutrition and medication

N=approx.

65 acutely admitted older medical patients with undernutrition or risk of undernutrition, and 35 without undernutrition or risk of undernutrition.

  1. Inter-professional optimisation of medication prescribing:

    Study participants in the intervention group receives optimisation of medication prescribing at admission day (baseline) regardless of nutritional state. The intervention is performed in cooperation between a clinical pharmacist and a medical physician.

  2. Nutritional intervention:

If positive screening for malnutrition or risk of malnutrition a dietetic intervention is initiated and if positive screening below interventions are initiated:

  • Dysphagia: occupational therapy intervention.
  • Oral cavity problems: odontological intervention.
  • Depression: geriatric intervention.
  • Low ADL: occupational therapy intervention and if positive screening for poor muscle strength: physiotherapeutic intervention.
Kein Eingriff: Standard care

N= approx. 65 acutely admitted older medical patients with undernutrition or risk of undernutrition, and 35 without undernutrition or risk of undernutrition.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Changes in quality of life score EuroQol- 5 Dimensions- 5 Levels (sub-study 1)
Zeitfenster: Baseline (admission day), week 8 and week 16.

Patient administered quality of life scoring system with focus on mobility, daily activities, pain and discomfort and depression.

Baseline (admission day), week 8 and week 16.
Changes in Medication Appropriateness Index-score" (sub-study 2)
Zeitfenster: Baseline (admission day), week 8 and week 16.

Medical physician, geriatric or senior pharmacist perform the MAI-scoring to evaluate the appropriateness of the medication prescribing.

Baseline (admission day), week 8 and week 16.
Accuracy of renal function estimates (sub-study 3) - cystatin C
Zeitfenster: Baseline (admission day) or no later than 14 days after admission

Differences between GFR measured by a renally excreted radioactive labeled isotope (chromium 51-Cr-EDTA or 99mTc diethylenetriaminepentaacetic acid) and estimated GFR based on Creatinine and Cystatin C or a combination of the biomarkers.

Baseline (admission day) or no later than 14 days after admission

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Walking speed to evaluate the development in physical performance
Zeitfenster: Baseline (admission day), week 8 and week 16.

4-Meter Walk Test

Baseline (admission day), week 8 and week 16.
Functional measurement to evaluate the development in physical performance
Zeitfenster: Baseline (admission day), week 8 and week 16.

30-second chair stand test

Baseline (admission day), week 8 and week 16.
Functional measurement to evaluate the development in physical performance
Zeitfenster: Baseline (admission day), week 8 and week 16.

handgrip strength test

Baseline (admission day), week 8 and week 16.
Functional measurement to evaluate the development in physical performance
Zeitfenster: Baseline (admission day), week 8 and week 16.

The de morton mobility index

Baseline (admission day), week 8 and week 16.
Measure of physically active time and number of steps taken
Zeitfenster: Week 1, week 8 and week 16 after discharge

Assessed by applying an activPAL chip to the thigh for one week

Week 1, week 8 and week 16 after discharge
Frailty assessment
Zeitfenster: Baseline (admission day), week 8 and week 16.

Fried frailty phenotype

Baseline (admission day), week 8 and week 16.
Frailty assessment
Zeitfenster: Baseline (admission day), week 8 and week 16.

Morleys frail questionnaire

Baseline (admission day), week 8 and week 16.
Anthropometric measurement to monitor changes in bodyweight
Zeitfenster: Baseline (admission day), week 8 and week 16.

Bodyweight

Baseline (admission day), week 8 and week 16.
Cognitive test aiming to evaluate cognitive function
Zeitfenster: Baseline (admission day), week 8 and week 16

Orientation Memory Concentration test

Baseline (admission day), week 8 and week 16
Patient records
Zeitfenster: Baseline (admission day), week 8 and week 16.

Contacts related to the health care system, medication lists, use of municipal services

Baseline (admission day), week 8 and week 16.
Standard admission blood work
Zeitfenster: Baseline (admission day), week 8 and week 16.

ALAT, albumin, alkaline phosphatase, bilirubin, CO2, CRP, haemoglobin, INR, K+, blood urea nitrogen, coagulation factors, leucocytes, neutrophils, MCH, MCV, Na+, thrombocytes, lactate-dehydrogenases, NGAL, β-trace protein and β-trace microglobulins.

Baseline (admission day), week 8 and week 16.
Quality of life score, WHO-5
Zeitfenster: Baseline (admission day), week 8 and week 16

Patient administered quality of life scoring system with focus on general well-being on a scale from 0-100.

Baseline (admission day), week 8 and week 16
Cognitive performance
Zeitfenster: Week 8 and week 16

Mini mental state examination

Week 8 and week 16
Cognitive performance
Zeitfenster: Week 8 and week 16

Hopkins verbal learning test

Week 8 and week 16
Cognitive performance
Zeitfenster: Week 8 and week 16

Trail making test

Week 8 and week 16
Cognitive performance
Zeitfenster: Week 8 and week 16

Digit Symbol Substitution test

Week 8 and week 16
Assessment of dietary intake after admission
Zeitfenster: Week 8 and week 16

24 hours dietary recall

Week 8 and week 16
Evaluation of medication under-prescribing
Zeitfenster: Baseline (admission day), week 8 and week 16

Assessment of underutilization Index (AOU)

Baseline (admission day), week 8 and week 16
Inflammatory marker to evaluate the inflammatory state
Zeitfenster: Baseline (admission day), week 8 and week 16.

SuPAR

Baseline (admission day), week 8 and week 16.
Polypharmacy
Zeitfenster: Baseline (admission day), week 8 and week 16.

The number of patients in polypharmacy

Baseline (admission day), week 8 and week 16.
Potentially inappropriate medication to elderly
Zeitfenster: Baseline (admission day), week 8 and week 16.

The number of potentially inappropriate medication prescriptions

Baseline (admission day), week 8 and week 16.
Acceptance of suggested changes in medications
Zeitfenster: Baseline (admission day), week 8 and week 16.

Frequency of physicians' acceptance of suggested changes in medications

Baseline (admission day), week 8 and week 16.
Accuracy of renal function estimates - all biomarkers
Zeitfenster: Baseline (admission day) or no later than 14 days after admission.

Differences between GFR measured by a renally excreted radioactive labeled isotope (chromium 51-Cr-EDTA or 99mTc diethylenetriaminepentaacetic acid) and estimated GFR based on Creatinine, Cystatin C, Beta-trace protein, Beta-2 microglobulin or a combination of the biomarkers.

Baseline (admission day) or no later than 14 days after admission.
Dosing discrepancies of renal risk medication
Zeitfenster: Baseline (admission day) or no later than 14 days after admission.

Frequency of renal risk medication prescribed in disagreement to clinical recommendation guidelines based on measured GFR and the choice of eGFR biomarker.

Baseline (admission day) or no later than 14 days after admission.
Nutritional status
Zeitfenster: Baseline (admission day), week 8 and week 16.

Screening scores for undernutrition with Mini Nutritional Assesment - Short Form, Eating validation scheme, Nutritional Risk Screening-2000

Baseline (admission day), week 8 and week 16.
Intestinal microbiome composition
Zeitfenster: Baseline (admission day), week 8 and week 16 after discharge.

Composition and changes in the intestinal microbiome.

Baseline (admission day), week 8 and week 16 after discharge.
Body composition
Zeitfenster: Baseline (admission day), daily through out admission, up to three weeks after admission during kidney function measurement, week 8 and week 16 after discharge.

Description and changes in body composition, assessed by bioelectric impedance analysis (InBodyS10).

Baseline (admission day), daily through out admission, up to three weeks after admission during kidney function measurement, week 8 and week 16 after discharge.
Body composition
Zeitfenster: Up to three weeks after admission during kidney function measurement

Assessed by dual x-ray absorptiometry (DXA)

Up to three weeks after admission during kidney function measurement

Andere Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Number and types of actionable gene variants - Pharmacogenetic test
Zeitfenster: Baseline (admission day)

The number of actionable gene variants identified by the pharmacogenetic test

Baseline (admission day)
Number and types of recommended therapy changes -Pharmacogenetic test
Zeitfenster: Baseline (admission day)

The number of actionable gene variants identified by the pharmacogenetic test

Baseline (admission day)
Health economy related to Sub-study 1
Zeitfenster: Baseline (admission day), week 8 and week 16 and 1 year after discharge

Health care costs will be evaluated in regards to changes in quality of life measured by EURO-Qol-5D-5L.

Baseline (admission day), week 8 and week 16 and 1 year after discharge

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Hauptermittler: Aino L. Andersen, MSc, Hvidovre University Hospital
  • Studienstuhl: Ove Andersen, MD, PhD, Hvidovre University Hospital

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

15. Oktober 2018

Primärer Abschluss (Tatsächlich)

30. August 2022

Studienabschluss (Tatsächlich)

30. August 2022

Studienanmeldedaten

Zuerst eingereicht

5. November 2018

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

12. November 2018

Zuerst gepostet (Tatsächlich)

14. November 2018

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

13. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

10. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren